Pharmacokinetic drug interaction profiles of proton pump inhibitors: An update

Drug Safety

Volumn 37, Issue 4, 2014, Pages 201-211

  Wedemeyer, Ralph Steven ^a   Blume, Henning ^a  

^a SocraTec CSC GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; BORTEZOMIB; CIPROFLOXACIN; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DIAZEPAM; ESOMEPRAZOLE; ETRAVIRINE; GEMIFLOXACIN; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LANSOPRAZOLE; LOPINAVIR; METHOTREXATE; MOSAPRIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NELFINAVIR; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PROGUANIL; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RABEPRAZOLE; RITONAVIR; THEOPHYLLINE; UNINDEXED DRUG; WARFARIN; CYTOCHROME P450 3A;

BINDING AFFINITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; HUMAN; PRIORITY JOURNAL; REVIEW; STOMACH PH; DRUG INTERACTION; METABOLISM; PHYSIOLOGY;

CYTOCHROME P-450 CYP2C19; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; PROTON PUMP INHIBITORS;

EID: 84899064750     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0144-0     Document Type: Review

References (136)

1. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112(6):1798-810.
2. Dammann HG. Pantoprazole: a pharmacological and clinical profile. Today's Ther Trends. 1997;15:109-36.
3. Cheer SM, Prakash A, Faulds D, et al. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs. 2003;63(1):101-33.
4. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash). 2000;40(1):52-62 quiz 121-3.
5. Lanza FL, Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol. 1998;93(11):2037-46.
6. Singh G, Triadafilopoulos G. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. Int J Clin Pract. 2005;59(10):1210-7.
7. Hanlon JT, Schmader KE, Koronkowski MJ, et al. Adverse drug events in high risk older outpatients. J Am Geriatr Soc. 1997;45(8):945-8.
8. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200-5.
9. Ramirez FC. Diagnosis and treatment of gastroesophageal reflux disease in the elderly. Clevel Clin J Med. 2000;67(10):755-66.
10. Blume H, Donath F, Warnke A, et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006;29(9):769-84.
11. Chin TW, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother. 1995;39(8):1671-5.
12. Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol. 1998;54(2):159-61.
13. Kofler S, Deutsch MA, Bigdeli AK, et al. Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. J Heart Lung Transpl. 2009;28(6):605-11.
14. Schaier M, Scholl C, Scharpf D, et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology (Oxford). 2010;49(11):2061-7.
15. Kofler S, Wolf C, Shvets N, et al. The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients. J Heart Lung Transpl. 2011;30(5):565-71.
16. Rupprecht K, Schmidt C, Raspe A, et al. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol. 2009;49(10):1196-201.
17. Arai K, Takeuchi Y, Watanabe H, et al. Prokinetics influence the pharmacokinetics of rabeprazole. Digestion. 2008;78:7-71.
18. Takeuchi Y, Watanabe H, Imawari M. Mosapride citrate, a serotonin HT 4 selective agonist, beneficially affects pharmacokinetics of proton pump inhibitor. Gastroenterology. 2005;128:A531.
19. Tomilo DL, Smith PF, Ogundele AB, et al. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy. 2006;26(3):341-6.
20. Fang AF, Damle BD, LaBadie RR, et al. Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects. Pharmacotherapy. 2008;28(1):42-50.
21. Iwamoto M, Wenning LA, Nguyen BY, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis. 2009;48(4):489-92.
22. Overton ET, Tschampa JM, Klebert M, et al. The effect of acid reduction with a proton pump inhibitor on the pharmacokinetics of lopinavir or ritonavir in HIV-infected patients on lopinavir/ritonavir-based therapy. J Clin Pharmacol. 2010;50(9):1050-5.
23. Singh K, Dickinson L, Chaikan A, et al. Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. Clin Pharmacol Ther. 2008;83(6):867-72.
24. Winston A, Back D, Fletcher C, et al. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS. 2006;20(10):1401-6.
25. Tappouni HL, Rublein JC, Donovan BJ, et al. Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. Am J Health Syst Pharm. 2008;65(5):422-8.
26. Pauli-Magnus C, Rekersbrink S, Klotz U, et al. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2001;364(6):551-7.
27. Gerson LB, Triadafilopoulos G. Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol. 2001;13(5):611-6.
28. Laine L. Proton pump inhibitor co-therapy with clopidogrel: is there GI benefit or cardiovascular harm? Gastroenterology. 2011;140(3):769-72.
29. Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther. 2010;31(8):810-23.
30. Lima JP, Brophy JM. The potential interaction between clopidogrel and proton pump inhibitors: a systematic review. BMC Med. 2010;8:81.
31. Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol. 2011;57(11):1251-63.
32. Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010;49(8):509-33.
33. Chen J, Yuan YC, Leontiadis GI, et al. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol. 2012;46:93-114.
34. Kwok CS, Loke YK. Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review. Drug Saf. 2012;35(2):127-39.
35. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937-44.
36. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713-8.
37. Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65-74.
38. Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821-7.
39. Frelinger AL, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59:1304-11.
40. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48(4):475-84.
41. BMS. Plavix prescribing information. 2011. http://products.sanofi.us/ plavix/plavix.html. Last accessed 23 April 2012.
42. Quinn DI, Nemunaitis J, Fuloria J, et al. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. Clin Pharmacokinet. 2009;48(3):199-209.
43. Washington C, Hou E, Hughes N, et al. Effect of omeprazole on bioavailability of an oral extended-release formulation of ciprofloxacin. Am J Health Syst Pharm. 2006;63(7):653-6.
44. Rocha A, Coelho EB, Sampaio SA, et al. Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers. Br J Clin Pharmacol. 2010;70(1):43-51.
45. Calabresi L, Pazzucconi F, Ferrara S, et al. Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers. Pharmacol Res. 2004;49(5):493-9.
46. Scholler-Gyure M, Kakuda TN, De Smedt G, et al. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers. Br J Clin Pharmacol. 2008;66(4):508-16.
47. Allen A, Vousden M, Lewis A. Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers. Chemotherapy. 1999;45(6):496-503.
48. Portoles A, Calvo A, Terleira A, et al. Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. J Clin Pharmacol. 2006;46(10):1195-203.
49. Wurtz M, Grove EL, Kristensen SD, et al. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart. 2010;96(5):368-71.
50. Kasprzak M, Kozinski M, Bielis L, et al. Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. Cardiol J. 2009;16(6):535-44.
51. Adamopoulos AB, Sakizlis GN, Nasothimiou EG, et al. Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomized crossover study. J Cardiovasc Pharmacol. 2009;54(2):163-8.
52. Bezabeh S, Mackey AC, Kluetz P, et al. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. Oncologist. 2012;17(4):550-4.
53. Andersson T, Cederberg C, Edvardsson G, et al. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther. 1990;47(1):79-85.
54. Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology. 1985;89(6):1235-41.
55. Ishizaki T, Chiba K, Manabe K, et al. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation. Clin Pharmacol Ther. 1995;58(2):155-64.
56. Funck-Brentano C, Becquemont L, Lenevu A, et al. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J Pharmacol Exp Ther. 1997;280(2):730-8.
57. Yu KS, Yim DS, Cho JY, et al. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001;69(4):266-73.
58. Prichard PJ, Walt RP, Kitchingman GK, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol. 1987;24(4):543-5.
59. Sutfin T, Balmer K, Bostrom H, et al. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit. 1989;11(2):176-84.
60. Unge P, Svedberg LE, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol. 1992;34(6):509-12.
61. Uno T, Sugimoto K, Sugawara K, et al. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. Ther Drug Monit. 2008;30(3):276-81.
62. Grass U. Drug interactions with proton pump inhibitors: cases reported internationally from medical practice [in German]. Der Kassenarzt. 2000;43:32-9.
63. Enderle C, Muller W, Grass U. Drug interaction: omeprazole and phenprocoumon. BMC Gastroenterol. 2001;1:2.
64. Iwao K, Saitoh H, Takeda K, et al. Decreased plasma levels of omeprazole after coadministration with magnesium-aluminium hydroxide dry suspension granules. Yakugaku Zasshi. 1999;119(3):221-8.
65. Andersson T, Bredberg E, Lagerstrom PO, et al. Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole. Eur J Clin Pharmacol. 1998;54(5):399-404.
66. Andersson T, Lundborg P, Regardh CG. Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol. Eur J Clin Pharmacol. 1991;40(1):61-5.
67. Soons PA, van den Berg G, Danhof M, et al. Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects. Eur J Clin Pharmacol. 1992;42(3):319-24.
68. Taburet AM, Geneve J, Bocquentin M, et al. Theophylline steady state pharmacokinetics is not altered by omeprazole. Eur J Clin Pharmacol. 1992;42(3):343-5.
69. Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol. 1992;14(4):288-92.
70. Reichenspurner H, Meiser BM, Muschiol F, et al. The influence of gastrointestinal agents on resorption and metabolism of cyclosporine after heart transplantation: experimental and clinical results. J Heart Lung Transpl. 1993;12(6 Pt 1):987-92.
71. Blohme I, Idstrom JP, Andersson T. A study of the interaction between omeprazole and cyclosporine in renal transplant patients. Br J Clin Pharmacol. 1993;35(2):156-60.
72. Bottiger Y, Tybring G, Gotharson E, et al. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther. 1997;62(4):384-91.
73. Kang BC, Yang CQ, Cho HK, et al. Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharm Drug Dispos. 2002;23(2):77-81.
74. Furuta T, Ohashi K, Kobayashi K, et al. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin Pharmacol Ther. 1999;66(3):265-74.
75. Cho JY, Yu KS, Jang IJ, et al. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. Br J Clin Pharmacol. 2002;53(4):393-7.
76. Yin OQ, Tomlinson B, Waye MM, et al. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics. 2004;14(12):841-50.
77. Wang LS, Zhou G, Zhu B, et al. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther. 2004;75(3):191-7.
78. Yasui-Furukori N, Takahata T, Nakagami T, et al. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol. 2004;57(4):487-94.
79. Palovaara S, Tybring G, Laine K. The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol. 2003;56(2):232-7.
80. Andersson T, Hassan-Alin M, Hasselgren G, et al. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001;40(7):523-37.
81. Drewelow B, Schaffler K, Reitmeir P. Superior interaction profile of pantoprazole vs esomeprazole after single dose diazepam regarding pharmacodynamic (PD) and kinetic (PK) parameters. Can J Gastroenterol. 2006;20(Suppl. A):144.
82. Drewelow B, Schaffler K, Reitmeir P, et al. Effects of multiple-dose esomeprazole and pantoprazole on diazepam pharmacokinetic profile and pharmacodynamic effects on cognitive and psychomotor function in healthy volunteers. Arzneimittelforschung. 2010;60(8):483-91.
83. Hartmann M, Bliesath H, Huber R, et al. Simultaneous intake of antacids has no influence on the pharmacokinetics of the gastric H+/K+-ATPase inhibitor pantoprazole. Gut. 1994;35(Suppl. 4):A76.
84. De Mey C, Meineke I, Steinijans VW, et al. Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction. Int J Clin Pharmacol Ther. 1994;32(2):98-106.
85. Hartmann M, Zech K, Bliesath H, et al. Pantoprazole lacks induction of CYP1A2 activity in man. Int J Clin Pharmacol Ther. 1999;37(4):159-64.
86. Huber R, Bliesath H, Hartmann M, et al. Pantoprazole does not interact with the pharmacokinetics of carbamazepine. Int J Clin Pharmacol Ther. 1998;36(10):521-4.
87. Padhi D, Harris R, Salfi M, et al. Cinacalcet HCl absorption in study subjects is not affected by coadministration of medications commonly prescribed to chronic kidney disease (CKD) patients (pantoprazole, sevelamer HCl, and calcium carbonate). J Am Soc Nephrol. 2003;14:SA-PO744.
88. Lorf T, Ramadori G, Ringe B, et al. Pantoprazole does not affect cyclosporin A blood concentration in kidney-transplant patients. Eur J Clin Pharmacol. 2000;55(10):733-5.
89. Gugler R, Hartmann M, Rudi J, et al. Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. Br J Clin Pharmacol. 1996;42(2):249-52.
90. Bliesath H, Huber R, Steinijans VW, et al. Lack of pharmacokinetic interaction between pantoprazole and diclofenac. Int J Clin Pharmacol Ther. 1996;34(4):152-6.
91. Hartmann M, Huber R, Bliesath H, et al. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. Int J Clin Pharmacol Ther. 1996;34(1 Suppl.):S67-71.
92. Heinze H, Fischer R, Pfutzer R, et al. Lack of interaction between pantoprazole and ethanol. Clin Drug Invest. 2001;2001(21):345-51.
93. Walter-Sack IE, Bliesath H, Stotzer F, et al. Lack of pharmacokinetic and pharmacodynamic interaction between pantoprazole and glibenclamide in humans. Clin Drug Invest. 1998;15:253-60.
94. Dietrich JW, Gieselbrecht K, Holl RW, et al. Absorption kinetics of levothyroxine is not altered by proton-pump inhibitor therapy. Horm Metab Res. 2006;38(1):57-9.
95. Koch HJ, Hartmann M, Bliesath H, et al. Pantoprazole has no influence on steady state pharmacokinetics and pharmacodynamics of metoprolol in healthy volunteers. Int J Clin Pharmacol Ther. 1996;34(10):420-3.
96. Hartmann M, Schulz HU, Krupp S, et al. Pantoprazole lacks interaction with the NSAID naproxen in man. Gut. 2000;47:A85.
97. Bliesath H, Huber R, Steinijans VW, et al. Pantoprazole does not interact with nifedipine in man under steady-state conditions. Int J Clin Pharmacol Ther. 1996;34(2):51-5.
98. Middle MV, Muller FO, Schall R, et al. Effect of pantoprazole on ovulation suppression by a low-dose hormonal contraceptive. Clin Drug Invest. 1995;9:54-6.
99. Ehrlich A, Fuder H, Hartmann M, et al. Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man. Eur J Clin Pharmacol. 1996;51(3-4):277-81.
100. Middle MV, Muller FO, Schall R, et al. No influence of pantoprazole on the pharmacokinetics of phenytoin. Int J Clin Pharmacol Ther. 1995;33(5):304-7.
101. Bliesath H, Hartmann H, Maier J, et al. Lack of interaction between pantoprazole and piroxicam in man. Gut. 2000;47:A85.
102. Lorf T, Ramadori G, Ringe B, et al. The effect of pantoprazole on tacrolimus and cyclosporin A blood concentration in transplant recipients. Eur J Clin Pharmacol. 2000;56(5):439-40.
103. Schulz HU, Hartmann M, Steinijans VW, et al. Lack of influence of pantoprazole on the disposition kinetics of theophylline in man. Int J Clin Pharmacol Ther Toxicol. 1991;29(9):369-75.
104. Duursema L, Muller FO, Schall R, et al. Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol. 1995;39(6):700-3.
105. Ferron GM, Paul JC, Fruncillo RJ, et al. Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults. J Clin Pharmacol. 1999;39(9):945-50.
106. St Peter JV, Awni WM, Granneman GR, et al. The effects of lansoprazole on the disposition of antipyrine and indocyanine green in normal human subjects. Am J Ther. 1995;2(8):561-8.
107. Lefebvre RA, Flouvat B, Karolac-Tamisier S, et al. Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther. 1992;52(5):458-63.
108. Gerloff J, Barth H, Migot A, et al. Does the proton pump inhibitor lansoprazole interact with antacids. Arch Pharmacol. 1993;347:A124.
109. Fuchs W, Sennewald R, Klotz U. Lansoprazole does not affect the bioavailability of oral contraceptives. Br J Clin Pharmacol. 1994;38(4):376-80.
110. Karol MD, Locke CS, Cavanaugh JH. Lack of pharmacokinetic interaction between lansoprazole and intravenously administered phenytoin. J Clin Pharmacol. 1999;39(12):1283-9.
111. Gremse DA. Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses. Expert Opin Pharmacother. 2001;2(10):1663-70.
112. Landes BD, Petite JP, Flouvat B. Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet. 1995;28(6):458-70.
113. Dilger K, Zheng Z, Klotz U. Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline. Br J Clin Pharmacol. 1999;48(3):438-44.
114. Granneman GR, Karol MD, Locke CS, et al. Pharmacokinetic interaction between lansoprazole and theophylline. Ther Drug Monit. 1995;17(5):460-4.
115. Kokufu T, Ihara N, Sugioka N, et al. Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol. 1995;48(5):391-5.
116. Takahashi K, Motohashi H, Yonezawa A, et al. Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism. Ann Pharmacother. 2004;38(5):791-4.
117. Itagaki F, Homma M, Yuzawa K, et al. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. J Pharm Pharmacol. 2004;56(8):1055-9.
118. Yasui-Furukori N, Saito M, Uno T, et al. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol. 2004;44(11):1223-9.
119. Vakily M, Lee RD, Wu J, et al. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies. Clin Drug Investig. 2009;29(1):35-50.
120. Humphries TJ. A review of the drug-drug interaction potential of rabeprazole sodium based on CYP-450 interference or absorption effects. Digestion. 1998;59(Suppl. 3):76.
121. Humphries TJ, Nardi RV, Spera AC, et al. Coadministration of rabeprazole sodium (E3810) does not affect the pharmacokinetics of anhydrous theophylline or warfarin. Gastroenterology. 1996;110:A138.
122. Itagaki F, Homma M, Yuzawa K, et al. Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation. Transpl Proc. 2002;34(7):2777-8.
123. Yasuda S, Higashi S, Murakami M, et al. Antacids have no influence on the pharmacokinetics of rabeprazole, a new proton pump inhibitor, in healthy volunteers. Int J Clin Pharmacol Ther. 1999;37(5):249-53.
124. Uno T, Shimizu M, Yasui-Furukori N, et al. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. Br J Clin Pharmacol. 2006;61(3):309-14.
125. Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther. 1999;13(Suppl. 3):18-26.
126. Andersson T, Holmberg J, Rohss K, et al. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol. 1998;45(4):369-75.
127. Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin Pharmacol Ther. 1994;55(4):402-11.
128. Naidu MUR, Shobha JC, Dixit VK, et al. Effect of multiple dose omeprazole on the pharmacokinetics of carbamazepine. Drug Invest. 1994;7:8-12.
129. Colin-Jones DG. Safety of lansoprazole. Aliment Pharmacol Ther. 1993;7(Suppl. 1):56-60 discussion 1-6.
130. Schouler L, Dumas F, Couzigou P, et al. Omeprazole-cyclosporin interaction. Am J Gastroenterol. 1991;86(8):1097.
131. Andersson T, Hassan-Alin M, Hasselgren G, et al. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001;40(6):411-26.
132. Oosterhuis B, Jonkman JH, Andersson T, et al. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol. 1991;32(5):569-72.
133. Fuhr U, Jetter A. Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie. 2002;57(9):595-601.
134. Battison L, Tulissi P, Moretti M, et al. Lansoprazole and ethanol metabolism: comparison with omeprazole and cimetidine. Pharmacol Toxicol. 1997;81:247-52.
135. Andersson T, Lagerstrom PO, Unge P. A study of the interaction between omeprazole and phenytoin in epileptic patients. Ther Drug Monit. 1990;12(4):329-33.
136. Hosohata K, Masuda S, Yonezawa A, et al. Absence of influence of concomitant administration of rabeprazole on the pharmacokinetics of tacrolimus in adult living-donor liver transplant patients: a case-control study. Drug Metab Pharmacokinet. 2009;24(5):458-63.